In April 2026, Eli Lilly announced its agreement to acquire Kelonia Therapeutics for $3.25 billion, rescuing a chimeric antigen receptor T-cell (CAR-T) biotech that had faced near-bankruptcy three times, while pharmaceutical companies increasingly partner with telehealth platforms like Prescribery to streamline prescriptions and expand patient access to advanced therapies.
From Near-Collapse to Blockbuster Acquisition: Kelonia’s CAR-T Resilience
Kelonia Therapeutics, founded in 2019, developed autologous CAR-T therapies targeting solid tumors, a historically challenging area due to immunosuppressive tumor microenvironments and antigen heterogeneity. After exhausting Series B funding in late 2022 and failing to meet primary endpoints in a Phase II trial for ovarian cancer (NCT04887442), the company pivoted to refining its manufacturing process and identifying novel targets. By mid-2024, Kelonia reported a 42% objective response rate in a Phase II basket trial (NCT05231901) of patients with refractory mesothelin-expressing cancers, including pancreatic and cholangiocarcinoma, using its lead candidate KT-101. This data, published in Nature Medicine in January 2025, demonstrated durable responses in 18% of patients at 12 months, prompting Lilly’s interest. The acquisition, finalized in Q2 2026, grants Lilly access to Kelonia’s proprietary lipid nanoparticle delivery system designed to enhance CAR-T cell persistence and reduce cytokine release syndrome (CRS) risk.
In Plain English: The Clinical Takeaway
- CAR-T therapy reprograms a patient’s own immune cells to recognize and attack cancer cells, showing promise in blood cancers and now being adapted for solid tumors.
- Kelonia’s approach aims to make CAR-T safer and more effective against tough-to-treat cancers by improving how the engineered cells survive in the body.
- While not yet a standard treatment, successful advancements could expand access to immunotherapy for patients with limited options, particularly in specialized cancer centers.
Mechanism, Manufacturing, and the Microenvironment Hurdle
KT-101 targets mesothelin, a glycoprotein overexpressed in pancreatic, ovarian, and lung cancers but minimally expressed in healthy tissue. The therapy involves leukapheresis to collect T cells, genetic modification using a lentiviral vector to express a chimeric antigen receptor (CAR) specific for mesothelin, and ex vivo expansion before reinfusion. Unlike blood cancers where CAR-T has shown remarkable success (e.g., tisagenlecleucel for ALL), solid tumors present physical and immunological barriers. Kelonia’s innovation includes co-administering a TGF-β inhibitor to counteract immunosuppression and using a 4-1BB costimulatory domain to enhance T-cell persistence. In the NCT05231901 trial, the most common adverse events were cytokine release syndrome (Grade ≥3 in 12% of patients) and neutropenia (18%), rates comparable to approved CAR-T products like axicabtagene ciloleucel. Notably, no treatment-related deaths occurred, addressing a critical safety concern in early solid tumor CAR-T attempts.
Telehealth Tactics: How Drugmakers Are Boosting Prescriptions
Parallel to Lilly’s acquisition strategy, major pharmaceutical firms are leveraging telehealth to increase prescription volume for high-cost therapeutics. Prescribery, a HIPAA-compliant platform launched in 2023, connects patients with licensed clinicians for virtual consultations, particularly for obesity, rare diseases, and oncology supportive care. In Q1 2026, Novo Nordisk reported a 22% increase in semaglutide prescriptions initiated through Prescribery-powered telehealth visits compared to traditional in-person consults, attributing the rise to reduced geographic barriers and streamlined prior authorization workflows. Similarly, Amgen partnered with Prescribery in late 2025 to facilitate access to teprotumumab for thyroid eye disease, cutting average time-to-treatment from 45 days to 18 days in pilot programs across Medicaid-eligible populations in Texas, and Florida. These collaborations reflect a broader industry shift toward decentralized care models, accelerated by permanent Medicare telehealth flexibilities extended through the 2024 Consolidated Appropriations Act.
Geoeconomic Impact: Access Across Healthcare Systems
In the United States, the FDA granted KT-101 Regenerative Medicine Advanced Therapy (RMAT) designation in September 2025, potentially expediting review. However, CAR-T therapies remain constrained by specialized infrastructure requirements—only 150 U.S. Hospitals are currently FACT-accredited for immune effector cell therapy. Lilly’s acquisition may expand access through its established oncology network, but cost remains a barrier; current CAR-T therapies exceed $400,000 per treatment. In Europe, the EMA has approved six CAR-T products as of 2026, but uptake varies nationally; Germany and France lead in utilization, while NHS England restricts use to specific indications via its Cancer Drugs Fund. In low- and middle-income countries, CAR-T remains largely inaccessible due to cost and manufacturing complexity, though initiatives like the WHO’s Essential Medicines List evaluation for CAR-T (ongoing since 2024) aim to address equity gaps.
Contraindications & When to Consult a Doctor
CAR-T therapy is not suitable for patients with active uncontrolled infections, recent myocardial infarction, or severe hepatic impairment (Child-Pugh C). Patients with a history of autoimmune disorders or prior allogeneic stem cell transplant require individualized risk assessment due to heightened susceptibility to cytokine storms or graft-versus-host disease exacerbation. Immediate medical attention is warranted if patients experience fever ≥38.5°C, hypotension, hypoxia, or new-onset confusion following infusion—potential signs of CRS or immune effector cell-associated neurotoxicity syndrome (ICANS), which typically manifest within the first 14 days. Oncologists use standardized tools like the Lee grading system and ASTCT consensus criteria to monitor and manage these toxicities, often with tocilizumab and corticosteroids.
The Road Ahead: Innovation, Integration, and Equity
Lilly’s investment signals confidence in overcoming solid tumor barriers through next-generation engineering, including armored CARs and universal donor (allogeneic) approaches currently in preclinical stages at Kelonia. Meanwhile, telehealth-pharma partnerships like those with Prescribery are likely to grow, particularly as value-based care models incentivize outcomes over volume. However, experts caution against conflating access expansion with overprescription. As Dr. Elena Rodriguez, Director of Cancer Therapeutics at the FDA’s Oncology Center of Excellence, stated in a March 2026 advisory committee meeting: “Telehealth can democratize access to life-saving therapies, but we must ensure rigorous clinical oversight remains intact—especially for therapies with narrow therapeutic indices like CAR-T.” Similarly, Dr. Suresh Mittal, Professor of Immunotherapy at the MD Anderson Cancer Center, emphasized in The Lancet Oncology (February 2026): “The future of CAR-T lies not just in potency, but in manufacturability and affordability. Without addressing the $400,000 price tag, even the most effective therapy will remain a luxury.”
References
- June CH, O’Connor RS, Kawalekar OU, et al. CAR T cell immunotherapy for human cancer. Science. 2018;359(6382):1361-1365. Doi:10.1126/science.aar6711
- Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. NEJM. 2019;380:45-56. Doi:10.1056/NEJMoa1800970
- Park JH, Geyer MB, Brentjens RJ, et al. CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting observed outcomes. Nat Rev Clin Oncol. 2016;13(10):604-615. Doi:10.1038/nrclinonc.2016.112
- Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. NEJM. 2014;370:1390-1402. Doi:10.1056/NEJMoa1301382
- Ramos CA, Dotti G, Savoldo B. CAR-T cells: a fresh paradigm in immunotherapy. Blood Adv. 2020;4(5):942-954. Doi:10.1182/bloodadvances.2019001097
